Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 1/20 | 0.54 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.54 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.48 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2855306 | 1.00 | ITGA4 (0.54) | ITGA4ITGB7GPR34TRPM8TACR1 | |
| SCHEMBL20394533 | 0.92 | ITGA4 (0.60) | ITGA4ITGB7TRPM8TACR1MAPT | |
| SCHEMBL4169003 | 0.92 | ITGA4 (0.60) | ITGA4ITGB7TRPM8TACR1MAPT | |
| SCHEMBL2860040 | 0.88 | EPHX2 (0.52) | ITGA4ITGB7MAPTNOS2MEN1 | |
| SCHEMBL2860038 | 0.88 | EPHX2 (0.52) | ITGA4ITGB7MAPTNOS2MEN1 | |
| SCHEMBL11347234 | 0.88 | NOS2 (0.59) | ITGA4ITGB7TRPM8POLBNOS2 | |
| SCHEMBL2863115 | 0.88 | NOS2 (0.59) | ITGA4ITGB7TRPM8POLBNOS2 | |
| SCHEMBL2863112 | 0.88 | NOS2 (0.59) | ITGA4ITGB7TRPM8POLBNOS2 | |
| Hydrochloric Acid SCHEMBL11347228 | 0.86 | NOS2 (0.58) | ITGA4ITGB7TRPM8POLBNOS2 | |
| SCHEMBL5887603 | 0.86 | ITGA4 (0.54) | ITGA4ITGB7TRPM8TACR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346971-B1 | Production method for biarylalanine | SUMITOMO CHEMICAL CO (JP) | 2010-01-20 | — | — | EP | disclosed |
| US-7091373-B2 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-15 | — | — | US | disclosed |
| US-20040024229-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-02-05 | — | — | US | disclosed |
| EP-1346971-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024229-A1 | Production method for biarylalanine | BCAT2, BCAT1, PAH | ITGA4 4068/4885ITGB7 4304/4885GPR34 3730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.